Metagenomi Inc (MGX) Stock Price, Quote & News

Company Profile

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensi...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 871 4880

Website: metagenomi.co

Address:

5959 Horton Street, 7th Floor, EmeryVille, United States

anachartanalyst Aug. 11 at 2:02 PM

$MGX https://anachart.com/wp-content/uploads/2026/08/1786456911_soc-img.jpg

0 · Reply

pumpandumpslut Aug. 7 at 3:54 PM

$MGX awful quiet here...

0 · Reply

Acs375 Jul. 6 at 3:58 PM

$MGX i heard that a bankruptcy is incoming. how true is that?

1 · Reply

Nanu108 Jun. 24 at 10:57 PM

$MGX I have a large position.

0 · Reply

focafoca99 Jun. 5 at 7:52 PM

$MGX faces a law-firm investigation over alleged fiduciary breaches by insiders.

1 · Reply

KHG1962 May. 28 at 10:06 PM

$MGX four posts in one month.

0 · Reply

KHG1962 May. 27 at 1:29 AM

$MGX No clue why I actually own this......

0 · Reply

Sam1381 May. 19 at 2:10 PM

$MGX 1.24$ so far today! Historic low 1.23$ New ATLs coming I gyess!

1 · Reply

anachartanalyst May. 12 at 2:02 PM

$MGX https://anachart.com/wp-content/uploads/2026/05/1778594491_soc-img.jpg

0 · Reply

BillionerOfKing May. 1 at 4:19 PM

$MGX Current Stock Price: $1.38

0 · Reply

Metagenomi price target lowered to $7 from $9 at Wells Fargo

Aug 10, 2026, 7:00 AM EDT - 9 days ago

Metagenomi Therapeutics Quarterly report: Q2 2026

Aug 10, 2026, 7:00 AM EDT - 9 days ago

Metagenomi Therapeutics Earnings release: Q2 2026

Jul 15, 2026, 8:00 AM EDT - 5 weeks ago

Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio

CLLS

2026-07-07T10:40:09.000Z - 6 weeks ago

Metagenomi transferred with a Buy at Chardan

Jun 9, 2026, 11:00 AM EDT - 2 months ago

Metagenomi Therapeutics Transcript: AGM 2026

Jun 5, 2026, 3:45 PM EDT - 2 months ago

Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Jun 4, 2026, 7:35 AM EDT - 2 months ago

Metagenomi Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

May 28, 2026, 8:00 AM EDT - 2 months ago

Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference

2026-05-12T10:27:58.000Z - 3 months ago

Metagenomi price target lowered to $9 from $12 at Wells Fargo

May 11, 2026, 4:05 PM EDT - 3 months ago

Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

May 11, 2026, 4:00 PM EDT - 3 months ago

Metagenomi Therapeutics Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 3 months ago

Metagenomi Therapeutics Quarterly report: Q1 2026

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Metagenomi Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Metagenomi Therapeutics Proxy statement: Proxy filing

2026-04-16T12:07:08.000Z - 4 months ago

Metagenomi announces publication on MG119-28

Apr 16, 2026, 7:00 AM EDT - 4 months ago

Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency

Mar 5, 2026, 4:05 PM EST - 5 months ago

Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results

Mar 5, 2026, 3:00 PM EST - 5 months ago

Metagenomi Therapeutics Annual report: Q4 2025

Mar 5, 2026, 3:00 PM EST - 5 months ago

Metagenomi Therapeutics Earnings release: Q4 2025

Mar 2, 2026, 11:10 AM EST - 6 months ago

Metagenomi Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 23, 2026, 4:05 PM EST - 6 months ago

Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference

Jan 12, 2026, 8:30 AM EST - 7 months ago

Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook

Dec 1, 2025, 7:00 AM EST - 9 months ago

Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference

Nov 20, 2025, 4:30 AM EST - 9 months ago

Metagenomi Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 8:00 AM EST - 9 months ago

Metagenomi to Present at Jefferies Global Healthcare Conference in London

2025-11-12T22:30:28.000Z - 9 months ago

Metagenomi price target lowered to $7 from $11 at Chardan

Nov 12, 2025, 7:00 AM EST - 10 months ago

Metagenomi Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

Metagenomi Therapeutics Quarterly report: Q3 2025

2025-11-11T21:11:48.000Z - 10 months ago

Metagenomi reports new dose range finding data from MGX-001 hemophilia A program

Nov 11, 2025, 4:02 PM EST - 10 months ago

Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates

Nov 11, 2025, 4:01 PM EST - 10 months ago

Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development

Oct 22, 2025, 10:02 AM EDT - 10 months ago

Metagenomi taps Amazon's custom chips to develop gene-editing tools

AMZN

2025-08-15T20:30:16.000Z - 1 year ago

Metagenomi price target lowered to $11 from $12 at Chardan

Aug 12, 2025, 4:05 PM EDT - 1 year ago

Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results

Aug 12, 2025, 7:00 AM EDT - 1 year ago

Metagenomi Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 1 year ago

Metagenomi Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 4:05 PM EDT - 1 year ago

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

KALV

May 15, 2025, 8:00 AM EDT - 1 year ago

Metagenomi Therapeutics Slides: Corporate Presentation

2025-05-14T10:21:54.000Z - 1 year ago

Metagenomi price target lowered to $16 from $20 at Wells Fargo

May 14, 2025, 6:00 AM EDT - 1 year ago

Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Metagenomi Reports Business Updates and First Quarter 2025 Financial Results

May 13, 2025, 4:00 PM EDT - 1 year ago

Metagenomi Therapeutics Quarterly report: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Metagenomi Therapeutics Earnings release: Q1 2025

May 2, 2025, 7:00 AM EDT - 1 year ago

Metagenomi to Present at Upcoming Scientific Meetings

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Metagenomi Therapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Metagenomi Therapeutics Proxy statement: Proxy Filing

Mar 17, 2025, 4:05 PM EDT - 1 year ago

Metagenomi Reports Business Updates and Full Year 2024 Financial Results

Mar 17, 2025, 9:30 AM EDT - 1 year ago

Metagenomi Therapeutics Earnings release: Q4 2024

Mar 17, 2025, 9:30 AM EDT - 1 year ago

Metagenomi Therapeutics Annual report: Q4 2024

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Metagenomi Therapeutics Registration statement: Registration Filing

Mar 13, 2025, 6:19 AM EDT - 1 year ago

Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems

Mar 5, 2025, 1:10 PM EST - 1 year ago

Metagenomi Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 11, 2025, 8:55 AM EST - 1 year ago

Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference

Jan 16, 2025, 8:55 AM EST - 1 year ago

Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones

Jan 15, 2025, 7:30 PM EST - 1 year ago

Metagenomi Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 8:55 AM EST - 1 year ago

Metagenomi Announces New Appointment to its Board of Directors

Jan 8, 2025, 4:05 PM EST - 1 year ago

Metagenomi to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 11, 2024, 6:30 PM EST - 1 year ago

Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference “RNA at the Bench and Bedside IV”

Dec 9, 2024, 9:16 PM EST - 1 year ago

Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting

Nov 23, 2024, 1:00 PM EST - 1 year ago

MGX Deadline: MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Lawsuit

Nov 22, 2024, 11:59 AM EST - 1 year ago

DEADLINE NEXT WEEK: Berger Montague Advises Metagenomi (NASDAQ: MGX) Investors to Contact the Firm Before November 25, 2024

anachartanalyst Aug. 11 at 2:02 PM

$MGX https://anachart.com/wp-content/uploads/2026/08/1786456911_soc-img.jpg

0 · Reply

pumpandumpslut Aug. 7 at 3:54 PM

$MGX awful quiet here...

0 · Reply

Acs375 Jul. 6 at 3:58 PM

$MGX i heard that a bankruptcy is incoming. how true is that?

1 · Reply

Nanu108 Jun. 24 at 10:57 PM

$MGX I have a large position.

0 · Reply

focafoca99 Jun. 5 at 7:52 PM

$MGX faces a law-firm investigation over alleged fiduciary breaches by insiders.

1 · Reply

KHG1962 May. 28 at 10:06 PM

$MGX four posts in one month.

0 · Reply

KHG1962 May. 27 at 1:29 AM

$MGX No clue why I actually own this......

0 · Reply

Sam1381 May. 19 at 2:10 PM

$MGX 1.24$ so far today! Historic low 1.23$ New ATLs coming I gyess!

1 · Reply

anachartanalyst May. 12 at 2:02 PM

$MGX https://anachart.com/wp-content/uploads/2026/05/1778594491_soc-img.jpg

0 · Reply

BillionerOfKing May. 1 at 4:19 PM

$MGX Current Stock Price: $1.38

0 · Reply

MikeEhrmantraut Apr. 22 at 2:27 PM

$MGX trash and pure management grift. Should be a university research department not a publicly traded company.

0 · Reply

Mindegap Apr. 20 at 7:50 PM

If I were short I would be nervous right now. Covering would be a very good option. $ABSI, $PRME, $MGX, $CRBU, $MXCT

1 · Reply

SuperGreenToday Apr. 17 at 9:51 PM

$MGX

0 · Reply

Mindegap Apr. 17 at 2:37 PM

$MGX Great News: $MGX created a tool that for the first time combines AAV-compatible size with therapeutic-grade editing efficiency — unlocking in vivo gene editing for tissues outside the liver that have been effectively unreachable until now. This enables next-generation editors that currently can't fit in AAV at all. Published in Nature. $PRME $BEAM

0 · Reply

DARKP00L Apr. 16 at 11:06 AM

$MGX 07:05 on Apr. 16 2026 Metagenomi Reports Study Showing CRISPR Editing Efficiency; Findings Support Development of Deliverable Gene Editing Systems #tradeideas

0 · Reply